Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Fluorescence Imaging Device Aids Wound Treatment

By MedImaging International staff writers
Posted on 22 Aug 2018
A novel wound imaging device digitally captures and documents fluorescence information from wounds and surrounding tissue using still images and videos in real-time.

The MolecuLight (Toronto, Canada) MolecuLight i:X is intended for point of care (POC) visualization and quantitative tracking of bacterial contamination, wound healing, and connective tissue remodeling of surgical sites and wounds, based on the detection of intrinsic fluorescence signals emitted by tissues and microbes when illuminated with specific wavelengths of light, without the need of contrast agents. Images can be captured and documented as either still images or videos of wounds, including in the surrounding areas where potentially harmful bacteria may be lurking.

MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and surrounding skin to emit a green fluorescence, while potentially harmful bacteria emit a red fluorescence. The device captures these red and green fluorescence signals in real time using specialized optical components to filter out the violet light, displaying the resultant image immediately on-screen. The MolecuLight i:X is precisely calibrated to detect fluorescent bacteria at levels higher than 104 CFU/g on a quantitative scale, or predominantly moderate to heavy growth on a semi-quantitative scale.

MolecuLight i:X illuminates the wound with a narrow band of violet light that causes endogenous fluorophores in the bacteria to fluoresce. Susceptible bacteria include Staphylocccus aureus and MRSA; Pseudomonas aeruginosa; Escherichia coli; Coagulase-negative staphylococci; multiple Enterococcus species; multiple Proteus species; Klebsiella pneumonia; Beta-hemolytic streptococci (Group B); and multiple Enterobacter species. It is recommended that imaging be performed after surface blood has been removed from the wound bed and peri-wound areas.

“The MolecuLight i:X platform is a significant advancement in the management of chronic wounds that is already revolutionizing wound care practice in Canada and Europe,” said Ralph DaCosta, PhD, founder, director, and chief scientific officer of MolecuLight. “Thousands of patients have already experienced a change in their assessment and treatment by clinicians who feel empowered by the wound fluorescence images they are seeing.”

Related Links:
MolecuLight


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Mobile Digital C-arm X-Ray System
HHMC-200D
PACS Workstation
CHILI Web Viewer
New
Breast Imaging Workstation
SecurView
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.